Glaukos Corporation tells stakeholders in its annual report delivered to the U.S. Securities and Exchange Commission this week it anticipates its corneal UV therapy to be approved by the FDA in 2023. “Our pharmaceutical iLink therapies, a suite of novel single-use drug formulations that are bio-activated by our proprietary systems, address both keratoconus and corneal ectasia, “Glaukos…
This content is viewable by members only. Visit MY ACCOUNT on the top menu to log in or to register for a 30 day free trial or purchase a subscription for UV Reporter 1 Year Single Membership or UV Reporter 1 Year Group Membership - $189 for first member and $25 for each additional member.
